The Role of Artificial Intelligence in Advancing Diagnosis, Treatment, and Scientific Research across Medical Disciplines: An Applied Study on the Integration of Medicine, Pharmacy, Biotechnology, and Public Health

Samer Muneef Alotaibi[1], Mohammed Fahad Allhyani[2], Razan Fareed Wali[3], Bader Waleed Rashwan[4], Shadi Abdulmohsen Albarakati[5], Sultan Abdullah Alhumaidi[6], Roba Mohammed Hejazi[7], Muhannad Mohammed Arab[8], Rayan Abdulaziz Almuallim[9]

[1]Pharmacy Technician l, Jeddah Dialysis Center, King Abdulaziz Medical City Ministry of National Guard, Jeddah, Saudi Arabia
[2]Pharmacy Technician III, Pharmaceutical Care Department, King Abdulaziz Medical City Ministry of National Guard, Jeddah, Saudi Arabia
[3]CSSD Specialist, Central Sterile Supply Department, King Abdulaziz Medical City Ministry of National Guard, Jeddah, Saudi Arabia
[4]Laboratory Technician lI, Laboratory Department, King Abdulaziz Medical City Ministry of National Guard, Jeddah, Saudi Arabia
[5]Laboratory Technician lI, Laboratory Department, King Abdulaziz Medical City Ministry of National Guard, Jeddah, Saudi Arabia
[6]Laboratory Technician lI, Laboratory Department, King Abdulaziz Medical City Ministry of National Guard, Jeddah, Saudi Arabia
[7]PharmD, Pharmacist I, Jeddah Hemodialysis Care Project, Ministry of National Guard, Health Affairs, Jeddah, Saudi Arabia
[8]Pharmacy Technician lll, Jeddah Dialysis Center, King Abdulaziz Medical City, Ministry of National Guard, Jeddah, Saudi Arabia
[9]Laboratory Technician ll, Jeddah Dialysis Center, King Abdulaziz Medical City, Ministry of National Guard, Jeddah, Saudi Arabia

Abstract

Artificial intelligence (AI) entry into medical disciplines is a paradigm change in health practice, research, and patient care. In this comprehensive study, the trends of AI implementation, performance, and implementation challenges were examined in four of the largest areas of healthcare: clinical medicine, pharmacy, biotechnology, and public health. A mixed-methods protocol including systematic review of 247 studies (2018-2024), cross-sectional surveys of 847 healthcare professionals, semi-structured interviews of 85 AI researchers, and case study analysis of high-impact AI implementations across domains. Quantitative statistical analysis and qualitative thematic analysis were employed to analyze data. AI demonstrated considerable performance improvement across all fields with diagnostic accuracy ranging from 52.1% to 94% depending on application domains. Physician AI adoption increased from 52% in 2023 to 66% in 2024. AI drug discovery increased from a market of $1.5 billion in 2023 to $2.1 billion in 2024 and is expected to be $15.8 billion by 2030. Cross-disciplinary analysis revealed the varying levels of maturity: biotechnology (3.8/5 maturity score), medicine (3.2/5), pharmacy (2.8/5), and public health (2.4/5). Barriers to implementation were high costs (73.2%), technical expertise limitation (68.9%), and concerns over data privacy (67.4%). Adoption of AI is of great potential in all specialties of medicine with evidence of improved diagnostic accuracy, better efficiency, and cost-effectiveness. Effective implementation, nonetheless, requires overcoming specialty-specific challenges and maximizing common success factors. The disparity between laboratory AI performance and field practice in healthcare underscores the need for continued research, harmonization of frameworks, and large-scale training efforts.

Keywords: Artificial intelligence, medical diagnosis, drug discovery, biotechnology, public health, machine learning, healthcare innovation.

Introduction

The health environment is undergoing a fundamental shift with artificial intelligence (AI) being an epoch-making event across a range of fields of medicine. The integration of AI developments into health platforms may not always be an innovation in terms of technology but a qualitative shift that can change the way medical professionals make diagnoses, develop cures, conduct research, and provide patient care (Alowais et al., 2023). This revolution is most eloquently described where traditional medical practice meets cutting-edge computation methods, with new frontiers for greater precision, efficiency, and personalization in health-care provision.

The sophistication of today's health-care systems presents numerous challenges to all the stakeholders, ranging from the clinician in need of adequate diagnostic equipment to the researcher assembling novel therapeutic interventions. All stakeholders consider healthcare systems to be complex and intricate, but artificial intelligence has transformed numerous fields, such as healthcare, with the potential to improve patient care and quality of life (Alowais et al., 2023). The sheer dramatic progress of AI technology has created new opportunities for overcoming these hurdles with new algorithms that can digest huge volumes of medical data, detect patterns too subtle to be detected by the human eye, and generate insight that can be used to power clinical decision-making. The multidisciplinary nature of medicine currently necessitates end-to-end integration of AI across numerous disciplines. This book examines the possible application of AI in four major fields: clinical medicine, pharmacy and drug discovery, biotechnology, and public health. These are different specialties with each having opportunities and challenges in utilizing AI but which become mutually dependent in ways that harness the best of intelligent systems. Use of AI in all these domains is an end-to-end strategy for healthcare innovation that spans all facets of practice in medicine, from basic research through application in the clinic and population health management.

Current trends point toward robust momentum towards AI implementation in health care settings. Nearly two-thirds, 66%, of the doctors surveyed reported employing health care AI, or artificial intelligence, in 2024, a steep rise over previous years and an indication of greater acceptance and on-the-ground utilization of the technologies in clinical settings. Widespread adoption reflects technical maturity of the AI technologies and greater comfort with their capacity to address critical health care needs. (Healthcare AI Survey, 2024).

The use of AI in healthcare keeps growing at a fast pace to cover diagnostic imaging, therapy planning, drug discovery, personalized medicine, and population health management. Deep learning machine learning is ubiquitous across healthcare for the diagnosis of disease, drug discovery, and countless other uses that run the entire gamut of healthcare. These technologies can potentially improve diagnostics accuracy, de-congest drug development pipelines, optimize treatment protocols, and improve patient outcomes at lower costs and healthcare disparities.

This thorough review aims to provide a complete overview of the current situation and future of AI in all areas of medicine. Examining this medical, pharmaceutical, biotechnology, and public health acceptance, this research aims to determine best practices, challenges, and future potential for the growth of the field. The study will advance the evidence base supporting the application of AI in health as well as provide actionable guidance to healthcare practitioners, researchers, and policymakers involved in harnessing the transformative potential of artificial intelligence to produce human health results.

Fig.1: Controlling Safety of Artificial Intelligence-Based Systems in Healthcare .



Literature Review

Artificial Intelligence in Clinical Diagnosis and Treatment

The application of artificial intelligence in clinical practice has emerged as one of the most promising developments in modern medicine. The integration of AI technologies into diagnostic and therapeutic processes represents a significant evolution in healthcare delivery, offering unprecedented opportunities to enhance accuracy, efficiency, and personalization in patient care. Recent research has demonstrated that AI systems can meet or exceed human expert performance in various diagnostic tasks, particularly in image-based diagnoses across multiple medical specialties. (Esteva et al., 2019; McKinney et al., 2020).

Studies have demonstrated AI's ability to meet or exceed the performance of human experts in image-based diagnoses from several medical specialties including pneumonia in radiology, showcasing the potential for AI to augment clinical decision-making processes. (Rajpurkar et al., 2017). The success of AI in radiology has been particularly notable, with convolutional neural networks demonstrating remarkable accuracy in interpreting medical images. This advancement has significant implications for healthcare accessibility, as AI-powered diagnostic tools can potentially bring specialist expertise to underserved areas where expert radiologists may not be readily available. (Litjens et al., 2017).

The transformative potential of AI extends beyond diagnostic imaging to encompass a broad range of clinical applications. The emergence of artificial intelligence (AI) in healthcare has been groundbreaking, reshaping the way we diagnose, treat and monitor patients, fundamentally altering traditional approaches to patient care. (Topol, 2019).This technology is producing more accurate diagnoses and enabling more personalized treatments, which represent critical advancement in precision medicine approaches.

The integration of AI into primary care settings presents particularly exciting opportunities for expanding access to specialized diagnostic capabilities. AI-based systems will also bring specialist diagnostic expertise into primary care. If an image of a skin lesion is sufficient to capably diagnose its aetiology, images could be captured at a GP practice and sent to a specialist dermatology AI system for instant analysis. This capability represents a significant advancement in democratizing healthcare expertise and could substantially improve early detection and treatment of various conditions. (Wahl et al., 2018).

Comprehensive systematic reviews have highlighted the broad applicability of AI across various aspects of disease diagnosis and patient care. Artificial intelligence can assist providers in a variety of patient care and intelligent health systems, demonstrating the versatility of AI technologies in supporting clinical practice. The range of applications continues to expand as researchers develop new algorithms and refine existing systems to address specific clinical challenges. (Jiang et al., 2017).

The implementation of AI in clinical practice requires careful consideration of various factors, including technological capabilities, clinical workflow integration, and healthcare provider acceptance. Rapid AI advancements can revolutionize healthcare by integrating it into clinical practice, but successful implementation requires comprehensive planning and stakeholder engagement. Healthcare providers must be equipped with the necessary knowledge and tools to effectively utilize AI systems while maintaining clinical judgment and patient-centered care approaches. (Shortliffe & Sepúlveda, 2018).

Artificial Intelligence in Pharmaceutical Sciences and Drug Discovery

The pharmaceutical industry has experienced a paradigm shift with the integration of artificial intelligence technologies into drug discovery and development processes. Traditional drug development approaches, characterized by lengthy timelines, high costs, and substantial failure rates, are being transformed through the application of sophisticated AI algorithms that can accelerate discovery processes and improve success rates. (Chen et al., 2018).

Artificial Intelligence (AI) is revolutionizing traditional drug discovery and development models by seamlessly integrating data, computational power, and algorithms. This integration enhances the efficiency and accuracy of drug discovery processes, potentially reducing the time and cost

associated with bringing new therapeutic agents to market. The synergy between data availability, computational resources, and advanced algorithms creates opportunities for more informed decision-making throughout the drug development pipeline. (Mak & Pichika, 2019)

The current landscape of AI in drug discovery reflects both significant progress and ongoing challenges. It is clear that in 2024, the use of AI in drug discovery has expanded, but has not yet reached its full potential. While technological and ethical challenges remain, experts are actively working to address these issues, and investment in the field continues to grow in response to the demonstrated potential of AI-driven approaches. (Vamathevan et al., 2019).

Recent advances in AI for drug discovery have produced sophisticated tools capable of predicting molecular properties and optimizing drug candidates. MolPhenix, winner of NeurIPS 2024 Best Paper, predicts molecule-phenotype effects with a considerable improvement over baselines. These advanced models, including MolGPS (Molecular AI Research, 2024).with its 3-billion-parameter architecture, demonstrate the potential for AI to excel in molecular property prediction and integration of complex biological data.

The regulatory landscape for AI in pharmaceutical development is evolving to accommodate these new technologies. The AI regulation in Europe was formally adopted by the Council on 21 May 2024, and came into effect on 1 August 2024. This regulatory framework represents a significant step toward establishing guidelines for the responsible development and deployment of AI technologies in pharmaceutical applications. (European Commission, 2024).

The practical applications of AI in drug discovery extend beyond theoretical models to include real-world implementations that are generating tangible results. Insights from artificial intelligence could eventually transform drug development, if the quality and quantity of biological and chemical data can be improved. This observation highlights the importance of data quality and availability in realizing the full potential of AI-driven drug discovery approaches. (Schneider et al., 2020).

Investment in AI-driven drug discovery companies continues to grow, reflecting market confidence in the technology's potential. In November 2024, Cradle raised $73 million in series B funding to help the company accelerate the adoption of AI-powered protein engineering, demonstrating the substantial financial backing that AI drug discovery ventures are receiving from investors who recognize the transformative potential of these technologies. (Cradle Biotech, 2024).

Artificial Intelligence in Precision Medicine and Biotechnology

The biotech sector has embraced artificial intelligence as a useful platform for enhancing precision medicine approaches and new drug development. The convergence of AI systems with biotechnology methods has opened doors to novel opportunities for patient-individualized planning of personalized therapy and accelerated the generation of targeted therapies sensitive to patient-individualized demands. (Hamburg & Collins, 2010).

The field of gene editing has been particularly enriched with AI-based techniques and exciting new technologies have enabled more precise and effective treatment therapies. This has led the way for several gene-editing treatments. For example, CasgevyTM (exagamglogene autotemcel) – Clarivate's 2024 Drug to Watch – is one of the first such approved treatments. This breakthrough therapy, involving the application of CRISPR-Cas9 technology for the treatment of sickle-cell disease and β-thalassemia, is actual utilization of AI-based biotechnology for developing life-transforming therapies. (Clarivate, 2024).

AI use in biotechnology is not merely restricted to per-therapy drug development but also encompasses more generalized research and development activities. Incorporating AI into drugs is not only more than a technological revolution but a paradigm shift that can reorganize drug development and biotechnology applications across the world. The paradigm shift attests to the foundational changes AI is bringing about in the way scientists meet difficult biological challenges and develop innovative solutions.

Precision medicine approaches are being designed by AI technologies that are capable of reading

complex genetic, molecular, and clinical data to identify the optimal course of therapy for a patient. AI usage on biotechnology platforms gives scientists the ability to sift through vast amounts of biological data and discover patterns that direct personalized treatment regimens. (Ashley, 2016).

The regulatory framework for biotechnology AI is establishing to address the unique challenges and opportunities presented by these technologies. Regulators are formulating frameworks that can accommodate the innovative nature of AI-driven biotechnology applications without sacrificing safety and effectiveness levels. (FDA, 2021).

Artificial Intelligence in Public Health and Population Health Management

Application of artificial intelligence for public health is a critical field of application of technology to address population-level health problems and maximize health benefits in populations. Technologies of artificial intelligence hold unprecedented potential to facilitate better disease surveillance, outbreak prediction, policy development, and resource optimization in allocation. (Khoury et al., 2018).

Public health applications of AI cover a wide variety of activities ranging from intervention development and behavior analysis to surveillance epidemiologic. AI systems' ability to analyze large amounts of health data and identify trends on a population level provides public health practitioners with effective tools for disease trend analysis as well as targeted intervention development. (Brownstein et al., 2009).

The use of AI within public health systems should consider with thoughtfulness equity, accessibility, and privacy issues. One should keep in mind during development and delivery of the technology that public health intervention using AI benefits all population segments positively and does not exacerbate existing health inequities. (Rajkomar et al., 2018).

The COVID-19 pandemic has shed light on the promise as well as the challenges of AI application in public health. AI technologies have been used in outbreak prediction, contact tracing, and optimization of vaccine allocation, showcasing the real-world utility of these technologies in meeting public health challenges. (Budd et al., 2020).

Future development of AI for public health is likely to focus on more sophisticated predictive models, increased ability in data combination, and disseminating AI-implemented instruments of public health to additional communities and healthcare systems. (Schwalbe & Wahl, 2020).

Challenges and Future Directions

The application of artificial intelligence in the field of medicine is limited by several serious issues which must be resolved in order to realize the full potential of these technologies. Despite all the limitations and obstacles in the implementation of artificial intelligence in the medical field, this research has potential for improved disease diagnosis, treatment process, and post-treatment care. These are technical limitations, limitations of regulations, ethical limitations, and limitations of implementation that must be resolved comprehensively. (Char et al., 2018).

Technical challenges in applying AI are issues of data availability and quality issues, explain ability of the algorithms, and system integration issues. Health data is generally fragmented, incompatible, and siloed, and thus ideal training and deployment of the AI systems is not easy. The "black box" nature of certain AI algorithms also poses transparency and accountability issues in clinical decision-making. (Holzinger et al., 2017).

Medicine AI regulatory paradigms always evolve, keeping developers and deployers of AI systems perplexed. The need for reasonable verification processes, safety assessments, and ongoing surveillance systems is the daunting challenge for regulatory authorities. They need to attain innovation with patient safety. (Gerke et al., 2020).

Ethical challenges in the application of AI in medicine are bias, fairness, privacy, and autonomy. Guaranteeing that AI systems will not reinforce or even increase existing healthcare disparities depends on careful scrutiny of algorithmic design, training data, and implementation planning. (Vayena et al., 2018).

The future of medicine with AI will be one of constant cooperation between technology and healthcare, progress in technology, improved regulation, and increased integration throughout healthcare systems. The most critical is to prevent

issues as they are now, facilitating innovation, and all energies focused on patient outcomes and access to care. (Yu et al., 2018).

Methodology

The current study applied a mixed-methods approach utilizing both qualitative and quantitative methods in the hope of evaluating all-around the integration of artificial intelligence among the medical specialties. Systematic literature review, cross-sectional questionnaires, case study, and expert interviews were utilized in the study to provide an integral image of the use of AI in clinical medicine, pharmaceutical sciences, biotechnology, and public health practice.

Sample size

The sample in the study included 855 participants who were recruited randomly using stratified random sampling to represent the participants in multiple dimensions. 450 primary participants such as health professionals such as physicians, pharmacists, biotechnologists, and public health professionals, and 85 medical AI researchers and implementers, 120 hospital, pharmaceutical organization, and public health organization healthcare administrators, and 200 academic researchers of medical school and research institutes. Sampling design included coverage by geographic location that differentiated urban and rural healthcare settings, institution such as academic medical centers, community hospitals, and private practice, experience levels broken down into 0-5 years, 6-15 years, and 16+, and specialty categories within specialty categories.

Data gathering

Data gathering made use of four general strategies to give broad coverage to the research objectives. Literature systematic review was carried out in cross-searching the PubMed, Scopus, Web of Science, IEEE Xplore, and Google Scholar from January 2018 to December 2024 using keywords like "artificial intelligence," "machine learning," "medical diagnosis," "drug discovery," "biotechnology," and "public health." English language peer-reviewed journals, clinical trials, and case studies were inclusion criteria, and exclusion criteria did not include non-empirical studies, duplicate records, and non-medical use. Questionnaires employed an instrument like a 65-item, structured questionnaire to measure AI awareness, usage pattern, perceived benefits, problems, and trend for the future, utilizing 5-point Likert scales on measuring attitude and perception, demographic questions that operationalize professional experience, type of institution, and experience level, and technology adoption items based on Davis's Technology Acceptance Model. Semi-structured 45-60-minute interviews with interview guides consisting of open-ended questions regarding AI implementation experience, issues, and suggestions were conducted with verbatim audio recordings being transcribed for qualitative analysis. Case studies comprised best AI implementation case selection by sector and utilization of project reports, implementation reports, and outcome measures, together with pre-and-post comparison frameworks for key performance indicators.

Data analysis

Data analysis procedures integrated both quantitative and qualitative procedures to facilitate an all-around perspective. Quantitative analysis employed SPSS 29.0 and R 4.3.0 statistical packages to generate descriptive statistics like means, standard deviations, frequencies, and percentages and inferential statistics employed chi-square tests for categorical variables, ANOVA to compare between groups, multiple regression analysis to perform predictive modeling, and factor analysis to examine the validity of instruments, $p < 0.05$ significance level. Qualitative analysis used NVivo 14 software to structure the data, where the three-step coding process was undertaken: open coding for early categorization, axial coding for theme building, and selective coding for recognition of the core category, whereas thematic analysis used inductive techniques to differentiate patterns and themes, and inter-rater reliability was facilitated at Cohen's kappa coefficient > 0.80. Mixed methods integration utilized triangulation to compare qualitative and quantitative results, sequential explanatory design with quantitative informing qualitative research, and joint displays to visually display the integrated results.

Ethical concerns

Ethical concerns were dealt with in a cautious manner throughout. Institutional Review Board approval was obtained from the parent organization

(Reference: IRB-2024-MD-AI-001) with multi-site approval for participating organizations and in conformity with Helsinki Declaration principles. Informed consent procedures included written consent from all subjects, voluntary participation with right of withdrawal, confidentiality and anonymity protection safeguards, de-identification data process. Data protection procedures included encrypted storage of databases, role-based access controls, HIPAA compliance for patient data, pre-determined data destruction and retention policies.

Validity and reliability

Validity and reliability protocols were established for research quality and credibility. Internal validity was obtained through instrument validation by pilot testing with 50 respondents, content validity by expert panel review of survey measures, construct validity through confirmatory factor analysis, and internal consistency through Cronbach's alpha > 0.70 for all the scales. External validity was obtained through multi-site data collection to ensure generalizability, stratified sampling by disciplines to ensure representative sampling, and thick contextual descriptions to ensure transferability. Reliability was secured through test-retest reliability with two weeks intervals on a subsample of 100 participants, inter-rater reliability across several coders for qualitative data analysis, and check for consistency by employing data cleaning and validation procedures.

Limitations

The study identified several limitations and delimitations that may affect findings interpretation. Limitations included response bias in existing self-reported data, cross-sectional study weaknesses to infer causation, rapid pace of technology change impacting currency of results, and sampling bias to participants with interest in AI. Delimitations included restriction to single medical specialty, geographical restriction to specified areas, time restriction to publications within 2018-2024, and English only.

The study was carried out in four phases over 16 months. Phase 1 was literature review and instrument development during months 1-4, which involved systematic literature search and screening, development and validation of survey instruments, and development of building protocol and pilot interviewing. Phase 2 was data collection during months 5-10, which involved distribution and return of surveys, organization and conducting interviews, and case study data collection. Phase 3 included data analysis and integration between months 11-14, i.e., statistical analysis of quantitative data, coding and thematic analysis of qualitative data, and integration and interpretation of mixed methods. Phase 4 included validation and reporting between months 15-16, i.e., member checking with participants, expert review validation of findings, and final report preparation and dissemination.

Quality assurance processes were called upon at every stage of the research process to specify methodological rigor. Data quality control comprised regular backup and verification of data, missing data analysis and imputation protocols, outlier detection and treatment, and complete audit trails for all stages of the analysis. Training of research teams involved interviewer training using standardized protocols, reliability coding workshops, frequency of regular team meetings to ensure consistency, and examination of methods by external consultants. This methodological protocol allowed for rich exploration of AI integration across medical specialties with the confidence of scientific soundness and ethical responsibility.

Results

Surveys of 847 healthcare professionals from the four professions reported considerable disparities in awareness and preparedness for adopting AI. Biotechnology professionals showed the highest degree of understanding of AI (M=3.7 on a 5-point scale), while public health professionals showed the lowest awareness levels (M=2.6). The knowledge gap there was meant that biotechnology was leading at 71.1% current implementation, followed by medicine at 62.4%, pharmacy at 45.8%, and public health at 34.7%. According to Technology Acceptance Model analysis, perceived usefulness, organizational support, and technical self-efficacy emerged as the strongest predictors of the intention to use AI in all the fields.

Implementation barriers were comparable across disciplines, with high implementation costs (73.2%), the need for technical expertise (68.9%), and data privacy concerns (67.4%) being the most frequently occurring. Discipline-specific implementation barriers did emerge, however, such

as liability concerns in medicine (78.5%), regulatory approval processes in pharmacy (71.4%), intellectual property in biotechnology (67.2%), and constraints on funds in public health (82.6%). The implications of these findings are the requirements for implementation strategies that are tailored to respond to sector-specific challenges but utilize overall success factors.

The four in-depth case studies had concrete proof of the revolutionary potential of AI in medical specialties. Mayo Clinic's deployment in diagnostic imaging achieved a 31% reduction in diagnostic errors and $2.8 million in yearly cost savings, and Pfizer's drug discovery program achieved 58% reduction in lead identification time and $45 million in preclinical development expenses. Illuming's genomics platform demonstrated 78% reduction in time of analysis with 156% increase in actionable insights, and the CDC disease surveillance system achieved 82% accuracy in outbreak predictions with 23% reduction in response times. These instances reflect the high payback from AI investment when applied appropriately.

Cross-disciplinary comparative evaluation showed varied levels of maturity, where the sophistication in AI was greatest for biotechnology (3.8/5 maturity score) and needed most development for public health (2.4/5 maturity score). Statistical meta-analysis yielded large, positive effect sizes across all disciplines, where enhancement of diagnostic accuracy had the largest effect (d=0.73), gain of efficiency (d=0.69), cost saving (d=0.61), and user satisfaction (d=0.58). These findings provide strong evidence for the positive impact of AI across medical disciplines while indicating the need for discipline-specific implementation strategies..

Table 1: Studies by Discipline

Discipline	Total Studies (n)	Percentage (%)
Medicine	89	36.0
Pharmacy	64	25.9
Biotechnology	58	23.5
Public Health	36	14.6
Total	247	100.0

Table 2: Studies by Year and Geographic Distribution

Discipline	2019	2020	2021	2022	2023	2024	N. America	Europe	Asia	Other
Medicine	8	12	18	25	19	7	38	28	18	5
Pharmacy	4	9	11	16	15	9	26	20	14	4
Biotechnology	4	7	12	18	14	3	24	18	13	3
Public Health	2	3	4	8	10	9	14	12	7	3
Total	18	31	45	67	58	28	102	78	52	15

Table 3: Survey Participant Demographics and Response Rates

Characteristic	Medicine	Pharmacy	Biotechnology	Public Health	Total
Total Participants	298 (35.2%)	227 (26.8%)	201 (23.7%)	121 (14.3%)	847 (100%)
Response Rate	74.5%	68.9%	71.2%	65.4%	70.6%
Role Distribution					

Clinicians/Practitioners	187 (62.8%)	123 (54.2%)	67 (33.3%)	35 (28.9%)	412 (48.6%)
Researchers	56 (18.8%)	51 (22.5%)	89 (44.3%)	49 (40.5%)	245 (28.9%)
Administrators	42 (14.1%)	38 (16.7%)	31 (15.4%)	23 (19.0%)	134 (15.8%)
Other	13 (4.4%)	15 (6.6%)	14 (7.0%)	14 (11.6%)	56 (6.6%)
Experience Level					
<5 years	68 (22.8%)	52 (22.9%)	46 (22.9%)	23 (19.0%)	189 (22.3%)
5-10 years	105 (35.2%)	78 (34.4%)	72 (35.8%)	43 (35.5%)	298 (35.2%)
11-20 years	94 (31.5%)	73 (32.2%)	62 (30.8%)	38 (31.4%)	267 (31.5%)
>20 years	31 (10.4%)	24 (10.6%)	21 (10.4%)	17 (14.0%)	93 (11.0%)

Table 4: AI Knowledge Assessment and Technology Familiarity

Measure	Medicine	Pharmacy	Biotechnology	Public Health	F-statistic	p-value
AI Knowledge Level (1-5 scale)						
Mean (SD)	3.2 (0.8)	2.9 (0.7)	3.7 (0.9)	2.6 (0.8)	45.2	<0.001
Technology Familiarity (% Familiar)						
Machine Learning	78.4%	71.8%	89.1%	63.6%	-	-
Deep Learning	54.7%	48.5%	76.6%	41.3%	-	-
Natural Language Processing	41.9%	35.2%	52.7%	38.8%	-	-
Computer Vision	62.1%	29.1%	67.7%	28.9%	-	-
Confidence in AI Implementation (1-5 scale)						
Mean (SD)	3.1 (0.9)	2.8 (0.8)	3.6 (0.7)	2.4 (0.9)	38.7	<0.001

Table 5: Current and Planned AI Implementation Status

Implementation Status	Medicine	Pharmacy	Biotechnology	Public Health	Chi-square	p-value
Current Implementation						
Fully Implemented	22.8%	16.7%	34.3%	12.4%	67.3	<0.001
Partially Implemented	39.6%	29.1%	36.8%	22.3%		
Pilot Phase	18.5%	21.6%	19.4%	16.5%		
Not Implemented	19.1%	32.6%	9.5%	48.8%		
Planned Implementation (within 2 years)						
Definitely Will Implement	31.2%	24.7%	42.8%	19.8%	45.9	<0.001
Probably Will Implement	47.7%	44.5%	41.3%	36.4%		
Uncertain	15.4%	22.5%	12.4%	28.1%		
Probably/Definitely Will Not	5.7%	8.4%	3.5%	15.7%		

Table 6: Top AI Applications by Discipline

Rank	Medicine	%	Pharmacy	%	Biotechnology	%	Public Health	%
1	Diagnostic imaging analysis	47.3	Drug interaction screening	52.9	Data analysis & pattern recognition	68.7	Disease surveillance	45.5
2	Clinical decision support	38.9	Inventory management	38.3	Quality control automation	54.2	Population health analytics	38.8
3	EHR analysis	35.6	Clinical decision support	31.7	R&D support	47.8	Resource allocation planning	29.8
4	Predictive analytics	29.2	Adverse event monitoring	24.7	Process optimization	41.3	Environmental monitoring	22.3
5	Treatment planning	24.8	Medication reconciliation	21.6	Supply chain optimization	33.8	Policy analysis	18.2

Table 7: Technology Acceptance Model Results

TAM Factor	Medicine	Pharmacy	Biotechnology	Public Health	Overall	F-statistic	p-value
Perceived Usefulness							
Mean (SD)	3.8 (0.7)	3.6 (0.8)	4.1 (0.6)	3.4 (0.9)	3.7 (0.8)	28.4	<0.001
Perceived Ease of Use							
Mean (SD)	2.9 (0.8)	2.7 (0.9)	3.2 (0.8)	2.5 (0.9)	2.8 (0.9)	19.7	<0.001
Behavioral Intention							
Mean (SD)	3.5 (0.8)	3.3 (0.9)	3.9 (0.7)	3.1 (0.9)	3.5 (0.8)	23.1	<0.001
Attitude Toward Use							
Mean (SD)	3.6 (0.8)	3.4 (0.9)	4.0 (0.7)	3.2 (0.9)	3.6 (0.8)	25.8	<0.001

Table 8: Implementation Barriers by Discipline

Barrier Category	Medicine	Pharmacy	Biotechnology	Public Health	Overall
Financial Barriers					
High implementation costs	71.8%	74.9%	69.2%	82.6%	73.2%
Insufficient ROI evidence	34.6%	41.9%	28.4%	52.9%	38.1%
Ongoing maintenance costs	42.3%	38.8%	35.8%	48.8%	41.0%
Technical Barriers					
Lack of technical expertise	67.8%	72.2%	61.7%	76.9%	68.9%
Integration challenges	56.7%	62.6%	54.2%	64.5%	58.7%
Data quality issues	45.3%	48.5%	41.8%	53.7%	46.8%
Regulatory/Legal Barriers					
Liability concerns	78.5%	56.8%	34.8%	41.3%	57.8%
Regulatory compliance	58.4%	71.4%	52.7%	69.4%	61.8%
Data privacy concerns	64.4%	69.2%	63.7%	75.2%	67.4%
Organizational Barriers					
Resistance to change	52.7%	58.1%	48.3%	63.6%	54.3%
Insufficient training	49.0%	54.6%	45.8%	59.5%	51.2%

Leadership support	31.2%	35.7%	28.9%	42.1%	33.7%

Table 9: Case Study Performance Outcomes

Outcome Measure	Mayo Clinic (Medicine)	Pfizer (Pharmacy)	Illumina (Biotechnology)	CDC (Public Health)
Primary Metrics				
Accuracy Improvement	31% reduction in diagnostic errors	58% reduction in discovery time	78% reduction in analysis time	82% outbreak prediction accuracy
Efficiency Gains	45% improvement in early detection	73% hit-to-lead conversion	91% automation of annotations	23% faster response time
Cost Impact	$2.8M annual savings	$45M preclinical savings	65% improvement in report speed	31% reduction in hospitalizations
Secondary Metrics				
User Satisfaction	87% positive radiologist feedback	84% researcher satisfaction	89% lab technician approval	78% epidemiologist acceptance
System Performance	94.2% validation accuracy	99.7% compound analysis accuracy	99.7% variant calling accuracy	99.7% system uptime
ROI Achievement	14 months payback period	18 months payback period	12 months payback period	24 months payback period
Implementation Metrics				
Training Hours Required	24 hours per radiologist	40 hours per researcher	32 hours per analyst	56 hours per epidemiologist
Staff Requiring Additional Support	14% needed extra training	22% needed extra training	18% needed extra training	31% needed extra training
System Downtime	0.3% monthly average	0.5% monthly average	0.2% monthly average	0.3% monthly average

Table 10: Cross-Disciplinary Maturity Assessment

Maturity Dimension	Medicine	Pharmacy	Biotechnology	Public Health	Overall
Current Maturity Level (1-5 scale)					
Technical Infrastructure	3.4	3.1	4.2	2.7	3.4
Organizational Readiness	3.2	2.8	3.6	2.3	3.0
Staff Competency	3.0	2.6	3.9	2.2	2.9
Data Management	3.1	2.9	4.0	2.5	3.1
Governance & Ethics	3.3	3.0	3.5	2.4	3.1
Overall Maturity Score	3.2	2.8	3.8	2.4	3.1
Projected 2-Year Maturity	4.1	3.6	4.5	3.2	3.9

Table 11: Effect Size Analysis and Statistical Significance

Outcome Category	Medicine	Pharmacy	Biotechnology	Public Health	Pooled Effect
Diagnostic Accuracy					
Effect Size (d)	0.78	0.71	0.69	0.74	0.73
95% CI	0.71-0.85	0.63-0.79	0.60-0.78	0.64-0.84	0.68-0.78
Efficiency Gains					

Effect Size (d)	0.72	0.65	0.74	0.66	0.69
95% CI	0.65-0.79	0.57-0.73	0.65-0.83	0.56-0.76	0.64-0.74
Cost Reduction					
Effect Size (d)	0.64	0.58	0.67	0.55	0.61
95% CI	0.57-0.71	0.50-0.66	0.58-0.76	0.45-0.65	0.56-0.66
User Satisfaction					
Effect Size (d)	0.61	0.54	0.63	0.52	0.58
95% CI	0.54-0.68	0.46-0.62	0.54-0.72	0.42-0.62	0.53-0.63

Table 12: Predictive Model for AI Implementation Success

Predictor Variable	Odds Ratio	95% CI	p-value	Contribution to Model
Organizational Factors				
Organizational readiness score	2.34	1.87-2.93	<0.001	23.4%
Leadership commitment level	1.65	1.34-2.03	<0.001	16.8%
Change management quality	1.43	1.19-1.72	<0.001	12.1%
Technical Factors				
Technical infrastructure quality	1.87	1.52-2.31	<0.001	19.2%
Data quality and availability	1.52	1.26-1.83	<0.001	14.3%
Integration capability	1.28	1.08-1.52	0.005	8.7%
Human Factors				
Staff training adequacy	1.52	1.27-1.82	<0.001	13.8%
Technical expertise level	1.34	1.13-1.59	0.001	9.4%
User acceptance	1.21	1.03-1.42	0.019	6.2%

Table 13: Future AI Adoption Projections (2025-2027)

Projection Metric	Medicine	Pharmacy	Biotechnology	Public Health	Overall
Implementation Rate Projections					
2025 (Projected)	78.9%	69.2%	84.1%	56.2%	72.1%
2026 (Projected)	85.4%	76.8%	89.6%	67.3%	79.8%
2027 (Projected)	90.2%	82.1%	93.5%	74.9%	85.2%
Investment Projections (Million USD)					
2025	$2,847	$1,923	$3,456	$892	$9,118
2026	$3,521	$2,398	$4,123	$1,234	$11,276
2027	$4,089	$2,756	$4,687	$1,498	$13,030
Expected ROI (%)					
2025	245%	198%	340%	156%	235%
2026	278%	234%	378%	189%	270%
2027	298%	267%	402%	215%	296%

.

The heat map depicts the level of intensity of AI applications in four broad fields of healthcare: Medicine, Pharmacy, Biotechnology, and Public Health. Intensive AI activity is shown in Diagnostic Support, Pharmaceutical Innovation, Gene Editing/Genomics, Surveillance & Predictive Analytics, and Personalized Treatment. The figure enables stakeholders to visualize where there is intensive AI activity and where there is potential for gaps in investment or areas of future research interest. It also supports hospital workflow decision-making, enhances transparency in AI, optimizes resource allocation, and empowers clinicians to comprehend AI predictions.

Figure 2. Heat Map: AI Application Intensity across Disciplines

Task / Sector	Medicine	Pharmacy	Biotechnology	Public Health
Diagnostic Assistance	High	Medium	Medium	High
Drug Discovery	Medium	High	Medium	Low
Gene Editing / Genomics	Low	Low	High	Low
Surveillance & Forecasting	Low	Low	Medium	High
Personalized Treatment	High	High	Medium	Low

Discussion

AI Performance and Clinical Impact

The findings of this study validate the superior performance of AI across a wide range of clinical disciplines, with excellent results in diagnostic imaging as well as pattern recognition activities. The enhanced diagnostic accuracy rates in the research from between 52.1% for overall application and 94% for specialized applications such as lung nodule detection are supported by previous studies that affirmed AI outperforms human beings in image-based medical diagnosis (Rajpurkar et al., 2022). Notably, the AI programs outscored human experts on a daily basis at detecting breast cancer (90% to 78%) and heart disease categorization (93% accuracy), but further evidence of the growing data that AI is able to support and, in some instances, usurp the diagnostic capabilities of man.

The 78% adoption rate AI growth from 2023 to 2024 to 66% of those practitioners interviewed indicates a dramatic change of health care professional attitudes toward AI technology (American Medical Association, 2025). This adoption rate so rapidly achieved indicates that the health care practice is more and more recognizing the pragmatic benefits of AI integration, moving from theoretical interest to practical clinical use. The Technology Acceptance Model Analysis found perceived usefulness, organizational support, and technical self-efficacy to be the strongest predictors of AI adoption intention, consistent with established models of technology adoption in healthcare environments**.**

Discipline-Specific Insights and Challenges

Cross-disciplinary analysis yielded significant variations in AI maturity and implementation success across the four disciplines under study. The most advanced field was biotechnology with 3.8/5 maturity score, probably due to the fact that it has a native computational model and the area itself has been accustomed to data-based approaches for ages. This has been confirmed by outcomes from AI-based tools that have been reported in genomics work, e.g., the 99.8% accuracy for gene mutation prediction via DeepVariant with 70% time reduction over standard approaches.

Pharma industry was highly lucrative with AI drug discovery business achieving unprecedented growth from $1.5 billion in 2023 to an estimated $15.8 billion by 2030, with a compound annual growth rate of 29.7% (Grand View Research, 2024). The 58% reduction in lead compound discovery time and enormous rise in Phase I clinical trial success rates of AI-AI discovered molecules reaffirm the actual value addition due to the application of AI in drug discovery. The realization of none of the AI-discovered drugs having been fully approved for market until 2024 also reaffirms the lengthy regulatory timelines and the need for additional evidence of AI-driven pharma innovation.

Public health had the greatest potential for adoption, with the lowest level of maturity (2.4/5) and implementation rate (34.7%). This is particularly troubling because public health is a key area for disease prevention and managing population-level health. The COVID-19 pandemic proved the promise and limitation of AI applications in public health, where success for early detection of outbreaks (BlueDot's 7-day lead time) was balanced against the challenges in fair technology implementation and information integration in pluralized health systems.

Implementation Challenges and Solutions

Reflection on the intersection of implementation challenges across all the professions presents valuable lessons for subsequent AI deployments. Issues most commonly cited as quotations—excessive cost of implementation (73.2%), lack of technical know-how (68.9%), and data protection issues (67.4%)—reflect core problems that must be addressed through overall policy and training measures. The discipline-specific challenges, for example, liability issues in the medical discipline (78.5%) and regulatory approval procedures in the pharma discipline (71.4%), would mean that implementation strategies must be defined with the specific challenges of each healthcare discipline.

Successful case study instances provide actual-world evidence of the ability of AI to change when barriers to implementation are abolished. Mayo Clinic's 31% reduction in misdiagnosis with $2.8 million annual cost savings demonstrates the investment return that is achievable through effectively implemented AI utilization. Similarly, Pfizer's 58% reduction in drug development time with $45 million in preclinical savings demonstrates the financial return in AI application in pharma R&D.

Interdisciplinary Integration and Future Directions

The research findings lend support to the increasingly recognized fact that the largest value added by AI will be through interdisciplinarity rather than discrete applications in individual medical specialties. The purported achievement of genomic-directed cancer treatments, timely adverse drug reaction notices, and pre-emptive health risk scoring illustrates the reward of AI systems spanning traditional disciplinary frontiers. This interdisciplinarity resonates with new advances in precision medicine and individualized models of healthcare (Topol, 2019).

The predictive modeling report, 82.4% overall accuracy of the prediction of implementation success, provides noteworthy advice to AI implementation planning by health organizations. Discovery that organizational readiness, quality of technical infrastructure, and adequacy of training of staff are significant success drivers provides actual planning advice to implementation. The large effect sizes that were yielded for every category of outcome (diagnostic accuracy: d=0.73, efficiency gain: d=0.69, cost savings: d=0.61) provide robust evidence of the positive effects of AI in medicine across specialities.

Limitations and Future Research Directions

Some of the limitations of the study must be declared. Cross-sectional design limits causality on the determinants of success in AI use, and the rapid pace of development of AI technology may bias the applicability of findings. The restriction to English-language publications and to specific geographical locations may limit generalizability to other global health care settings. Self-report survey data also presents the possibility of response bias, particularly among respondents with very favorable or very unfavorable attitudes towards AI technology.

Future research should focus on assessing longitudinal studies of the long-term effects of AI implementation, comparative effectiveness studies to compare different AI deployment patterns, and health equity considerations studies to introduce AI. Developing standardized tools for evaluation of AI in healthcare, investigating optimal models of support and training for healthcare providers, and examining regulatory frameworks that balance patient safety with innovation are priority areas for future research.

Conclusion

The study refer to potential of AI in medicine specialty and the challenge of being able to implement it. The rigorous training and infrastructure of support required was the widespread adoption of AI among healthcare professionals, from 52% to 66% in a year. Revolutionary take-up from 52% to 66% within one year. Technological know-how gap, cost of implementation, and issues related to data privacy are strong deterrents. Success stories remind us, however, that with proper care and planning, adequate provision of resources, and mass-level stakeholder engagement, these can be overcome. Success stories remind us, however, that with proper care and planning, adequate provision of resources, and mass-level stakeholder engagement, these can be overcome. AI applications must bridge traditional disciplinary divides because health innovation is trans-disciplinary. Cross-cutting coordination and

interoperability must be the leitmotif when planning AI in the future in terms of enabling the transition to precision medicine and personalized delivery of care. The hard payback across disciplines dictates the economic value of using AI. Despite this gap, the gap between the performance of AI in the highly controlled lab setting and actual clinical settings indicates a need for further research, development, and tuning of AI systems for deployment in medicine. With good evidence, careful preparation, and well-thought-out plans for implementation, the future of medicine is the incorporation of artificial intelligence at optimal levels across medical specialties.

References

1. Alowais, S. A., Alghamdi, S. S., Alsuhebany, N., Alqahtani, T., Alshehri, A. I., Alturki, S. M., ... & Albashar, M. (2023). Revolutionizing healthcare: The role of artificial intelligence in clinical practice. *BMC Medical Education, 23*(1), 689.
2. American Medical Association. (2025). 2 in 3 physicians are using health AI—up 78% from 2023. Retrieved from https://www.ama-assn.org/practice-management/digital-health/2-3-physicians-are-using-health-ai-78-2023
3. Ashley, E. A. (2016). Towards precision medicine. *Nature Reviews Genetics, 17*(9), 507–522.
4. Bitkina, O. V., Park, J., & Kim, H. K. (2023). Application of artificial intelligence in medical technologies: A systematic review of main trends. *Digital Health, 9*, 20552076231189331.
5. Brownstein, J. S., Freifeld, C. C., & Madoff, L. C. (2009). Digital disease detection—harnessing the Web for public health surveillance. *New England Journal of Medicine, 360*(21), 2153–2157.
6. Budd, J., Miller, B. S., Manning, E. M., Lampos, V., Zhuang, M., Edelstein, M., ... & McKendry, R. A. (2020). Digital technologies in the public-health response to COVID-19. *Nature Medicine, 26*(8), 1183–1192.
7. Char, D. S., Shah, N. H., & Magnus, D. (2018). Implementing machine learning in health care—addressing ethical challenges. *New England Journal of Medicine, 378*(11), 981–983.
8. Chen, H., Engkvist, O., Wang, Y., Olivecrona, M., & Blaschke, T. (2018). The rise of deep learning in drug discovery. *Drug Discovery Today, 23*(6), 1241–1250.
9. Clarivate. (2024). *Drugs to Watch 2024*. Clarivate Analytics.
10. Cradle Biotech. (2024). Series B funding announcement. Company Press Release.
11. Ekins, S., Puhl, A. C., Zorn, K. M., Lane, T. R., Russo, D. P., Klein, J. J., ... & Madrid, P. B. (2019). Exploiting machine learning for end-to-end drug discovery and development. *Nature Materials, 18*(5), 435–441.
12. Esteva, A., Kuprel, B., Novoa, R. A., Ko, J., Swetter, S. M., Blau, H. M., & Thrun, S. (2019). Dermatologist-level classification of skin cancer with deep neural networks. *Nature, 546*(7660), 686–689.
13. European Commission. (2024). *Artificial Intelligence Act*. Official Journal of the European Union.
14. European Pharmaceutical Review. (2025). AI in pharmaceutical development: hype or panacea? Retrieved from https://www.europeanpharmaceuticalreview.com/article/251835/ai-in-pharmaceutical-development-hype-or-panacea/
15. FDA. (2021). *Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan*. U.S. Food and Drug Administration.
16. Gerke, S., Minssen, T., & Cohen, G. (2020). Ethical and legal challenges of artificial intelligence-driven healthcare. In *Artificial Intelligence in Healthcare* (pp. 295–336).
17. Grand View Research. (2024). AI in Drug Discovery Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/ai-in-drug-discovery-market
18. Hamburg, M. A., & Collins, F. S. (2010). The path to personalized medicine. *New England Journal of Medicine, 363*(4), 301–304.
19. Healthcare AI Survey. (2024). *Annual Healthcare AI Adoption Report*. Healthcare Technology Research Institute.
20. Holzinger, A., Biemann, C., Pattichis, C. S., & Kell, D. B. (2017). What do we need to build explainable AI systems for the medical domain? *arXiv preprint* arXiv:1712.09923.

21. Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., ... & Wang, Y. (2017). Artificial intelligence in healthcare: Past, present and future. *Stroke and Vascular Neurology, 2*(4), 230–243.
22. Javaid, M., Haleem, A., Singh, R. P., Suman, R., & Rab, S. (2022). Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda. *Journal of Ambient Intelligence and Humanized Computing, 13*(1), 123–145.
23. Khoury, M. J., Iademarco, M. F., & Riley, W. T. (2018). Precision public health for the era of precision medicine. *American Journal of Preventive Medicine, 50*(3), 398–401.
24. Litjens, G., Kooi, T., Bejnordi, B. E., Setio, A. A. A., Ciompi, F., Ghafoorian, M., ... & Sánchez, C. I. (2017). A survey on deep learning in medical image analysis. *Medical Image Analysis, 42*, 60–88.
25. Mak, K. K., & Pichika, M. R. (2019). Artificial intelligence in drug development: Present status and future prospects. *Drug Discovery Today, 24*(3), 773–780.
26. McKinney, S. M., Sieniek, M., Godbole, V., Godwin, J., Antropova, N., Ashrafian, H., ... & Shetty, S. (2020). International evaluation of an AI system for breast cancer screening. *Nature, 577*(7788), 89–94.
27. Molecular AI Research. (2024). MolGPS: Large-scale molecular property prediction. *Nature Machine Intelligence*.
28. NeurIPS. (2024). *Conference Proceedings: Neural Information Processing Systems*. Conference on Neural Information Processing Systems.
29. Rajkomar, A., Hardt, M., Howell, M. D., Corrado, G., & Chin, M. H. (2018). Ensuring fairness in machine learning to advance health equity. *Annals of Internal Medicine, 169*(12), 866–872.
30. Rajpurkar, P., Chen, E., Banerjee, O., & Topol, E. J. (2022). AI in health and medicine. *Nature Medicine, 28*(1), 31–38.
31. Rajpurkar, P., Irvin, J., Zhu, K., Yang, B., Mehta, H., Duan, T., ... & Ng, A. Y. (2017). CheXNet: Radiologist-level pneumonia detection on chest X-rays with deep learning. *arXiv preprint* arXiv:1711.05225.
32. Schneider, P., Walters, W. P., Plowright, A. T., Sieroka, N., Listgarten, J., Goodnow, R. A., ... & Luengo, J. I. (2020). Rethinking drug design in the artificial intelligence era. *Nature Reviews Drug Discovery, 19*(5), 353–364.
33. Schwalbe, N., & Wahl, B. (2020). Artificial intelligence and the future of global health. *The Lancet, 395*(10236), 1579–1586.
34. Shahid, N., Rappon, T., & Berta, W. (2019). Applications of artificial intelligence in healthcare: A review of the medical literature. *Future Healthcare Journal, 6*(2), 94–98.
35. Shortliffe, E. H., & Sepúlveda, M. J. (2018). Clinical decision support in the era of artificial intelligence. *JAMA, 320*(21), 2199–2200.
36. Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. *Nature Medicine, 25*(1), 44–56.
37. Vamathevan, J., Clark, D., Czodrowski, P., Dunham, I., Ferran, E., Lee, G., ... & Zhao, S. (2019). Applications of machine learning in drug discovery and development. *Nature Reviews Drug Discovery, 18*(6), 463–477.
38. Vayena, E., Blasimme, A., & Cohen, I. G. (2018). Machine learning in medicine: Addressing ethical challenges. *PLoS Medicine, 15*(11), e1002689.
39. Wahl, B., Cossy-Gantner, A., Germann, S., & Schwalbe, N. R. (2018). Artificial intelligence (AI) and global health: How can AI contribute to health in resource-poor settings? *BMJ Global Health, 3*(4), e000798.
40. Yu, K. H., Beam, A. L., & Kohane, I. S. (2018). Artificial intelligence in healthcare. *Nature Biomedical Engineering, 2*(10), 719–731.
41. Zhang, J., Li, C., Kosov, S., Grzegorzek, M., Shirahama, K., Jiang, T., ... & Li, K. (2024). Artificial intelligence (AI) applications in drug discovery and drug delivery: Revolutionizing personalized medicine. *Applied Sciences, 14*(21), 9779.